Abbott unveils late-breaking data showing the world's first dual-chamber leadless pacemaker study met all three primary endpoints

Abbott's aveir™ dr i2i™ ide study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker the study successfully met all three of its primary safety and performance endpoints abbott's investigational aveir dr leadless pacemakers have been submitted for evaluation by the u.s. fda new orleans , may 20, 2023 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking results from the aveir™ dual-chamber (dr) i2i™ investigational device exemption (ide) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. the data further suggests that aveir dr could offer new benefits for people with slower-than-normal heart rhythms.
ABT Ratings Summary
ABT Quant Ranking